The objective of the symposium is to educate on:

• The role of inflammation in atherosclerosis.
• That “residual inflammatory risk” is distinct from “residual cholesterol risk” and hence an independent risk factor for atherosclerosis.
• How residual inflammatory risk can be easily diagnosed with available biomarkers – e.g., elevated hsCRP.
• The role for tailored therapeutic strategies to reduce residual inflammatory risk to improve outcomes for post-MI patients.